期刊文献+

增殖型糖尿病性视网膜病变玻切术后再出血原因分析及处理 被引量:2

Causes and management of rebleeding after vitrectomy for proliferative diabetic retinopathy
暂未订购
导出
摘要 目的:研究增殖型糖尿病性视网膜病变玻切术后再出血原因分析及处理。方法:选取2017年1月-2019年5月增殖型糖尿病性视网膜病变玻切术后再出血患者40例,分析再出血的原因,同时采取有效的处理对策。结果:激光量不足、取出硅油、白内障手术后、新生血管性青光眼、纤维血管膜残端、视网膜新生血管及视网膜中央静脉阻塞等均是导致术后再出血的原因。实施睫状体冷冻、周边视网膜冷冻、注入硅油、再玻切、内激光、剥膜、灌洗及激光视网膜光凝等相关治疗可有效预防术后再出血。结论:导致增殖型糖尿病性视网膜病变玻切术后出现再出血的原因十分复杂,为降低术后再出血发生率,需实施针对性治疗。 Objective:To explore the causes and management of rebleeding after vitrectomy for proliferative diabetic retinopathy.Methods:From January 2017 to May 2019,40 patients with rebleeding after vitrectomy for proliferative diabetic retinopathy were selected.We analyzed the causes of rebleeding and took effective countermeasures.Results:The causes of postoperative rebleeding included insufficient laser volume,silicone oil removal,cataract surgery,neovascular glaucoma,fibrous vascular membrane stump,retinal neovascularization and central retinal vein occlusion.The treatment of cryosurgery of ciliary body,cryosurgery of peripheral retina,silicone oil injection,re vitrification,internal laser,membrane peeling,irrigation and laser photocoagulation of retina can effectively prevent postoperative rebleeding.Conclusion:The causes of rebleeding after vitrectomy for proliferative diabetic retinopathy are complex,in order to reduce the incidence of postoperative rebleeding,targeted treatment is needed.
作者 吕振兴 张风禄 Lv Zhenxing;Zhang Fenglu(Guangming Eye Hospital of Liaocheng City,Shandong Liaocheng 252000)
出处 《中国社区医师》 2020年第21期56-56,58,共2页 Chinese Community Doctors
关键词 增殖型糖尿病性视网膜病变 玻璃体切除手术 再出血 处理对策 Proliferative diabetic retinopathy Vitrectomy Rebleeding Management
  • 相关文献

参考文献5

二级参考文献40

  • 1李凤鸣.中华眼科学[M].北京:第2版.人民卫生出版社,2005:2165-2171.
  • 2Ahn J,Woo SJ,Chung H,et al.The effect of adjunctive intravit- real bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy [J].Ophthalmology, 2011, 118 ( 11 ) : 2218-2226.
  • 3Schmidt-Erfurth U. Clinical safety of ranibizumab in age-relat- ed macu-lar degeneration[J]. Expert Opin Drug Saf, 2010, 9 ( 1 ) : 149-165.
  • 4Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema(Resolve Study):a 12- month,randomized, controlled, doublemasked, multicenter phase 1I studv[J]. Diabetes Care.2010.33(ll) :2399-2405.
  • 5Blick SK, Keating GM, Wagstaff AJ.Ranibizumab[J].Drugs, 2007 ; 67(8) : 1199-1206.
  • 6Singer MA,Awh CC,Sadda S,et al.HORIZON:an open-label ex- tension trial of ranibizumab for choroidal neovascularization sec- ondary to agerelated macular degenera [J]. Ophthalmology,2012,119(6):1175-1183.
  • 7Suzuki Y, Suzuki K , Yokoi Y , et al. Effects of intravitreal injection ofbevacizumab on inflammatory cytokines in the vitreous with proliferativediabetic retinopathy[J] . R etina, 2 0 1 4 ,3 4 (1 ) : 165 -1 7 1 .
  • 8王丽英,张月玲,苏陆青,等.增殖性糖尿病性视网膜病变玻璃体切除术后发生新生血管性青光眼的原因分析[J] . 中国医药导刊,2 0 1 2 ,4 (2 3 ) :29 - 3 0 .
  • 9Beebe D C, Shui YB , Siegfried C J, et al. Preserve the( intraocular) environment:the importance of maintaining normal oxygen gradients in thee y e [J]. Jpn J Ophthalmol, 2 0 1 4 ,5 8 (3 ) :225 -2 3 1 .
  • 10中华人民共和国卫生部. 新药(西药)临床研究指导原则汇编[M].中华人民共和国卫生部药政局,1993.

共引文献38

同被引文献28

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部